Patients may be asked by their physician to donate tubes of blood for scientific research.
The tubes of blood are shipped to a laboratory where DNA, RNA, proteins, and cells are isolated. The isolated materials are sent for sophisticated, cutting-edge, scientific analysis.
Rheumatoid Arthritis (RA)
CorEvitas has collected over 80,000 samples from patients with rheumatoid arthritis. Scientists are currently using these samples to better match a patient to the optimal treatment and to determine why some treatments are not as effective as others.
Inflammatory Bowel Disease (IBD)
To better understand IBD, scientists demonstrate interactions between genetics, microbiome, and a patient's environment. CorEvitas' longitudinal registry allows scientists to disentangle these complex interactions.
Multiple Sclerosis (MS)
The interplay between molecular imaging, blood proteins, RNA, and DNA provides transformative molecular understanding for this disease. Advances in machine-learning now make it possible to better analyze images and compare this to outcomes, improved treatments, and molecular markers of disease severity.
Understanding the interplay between the immune system, the microbiome, and genetics is the key to understanding this disease. Skin samples, paired with immune profiling makes this an excellent disease where samples from patients will aid scientists.
Spondyloarthritis and Psoriatic Arthritis
We hope to identify and reduce the suffering in patients with these diseases. Better understanding of the cause, severity, and duration of disease is only possible with well documented samples.
Over 80,000 longitudinal samples collected from patients diagnosed with rheumatoid arthritis.
CorEvitas carried out the largest, most comprehensive study in patients starting or switching therapy for rheumatoid arthritis. Patients donated plasma, serum, DNA, and RNA. CorEvitas partnered with diagnostic and therapeutic companies that transformed these samples into meaningful, clinically relevant results. We partner with innovative companies and academic institutions with transformative research goals and interests that improve patient care.
CorEvitas collected multiple samples from patients prior to initiating treatment and at 3 months post treatment.
Multiple sample types
Plasma, serum, RNA, miRNA, and DNA available.
Deep Clinical Data
Patients followed using CorEvitas' proprietary data collection protocol with follow-up through the course of treatment.
CorEvitas is developing deep omic data consisting of whole-genome sequencing, RNA-Seq, immunoprofiling, and proteomics available for licensing.